Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4606-4613

  Sabichi, Anita L ^a   Xu, Hui ^a   Fischer, Susan ^a   Zou, Changchan ^a   Yang, Xiulan ^a   Steele, Vernon E ^b   Kelloff, Gary J ^b   Lotan, Reuben ^a   Clifford, John L ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; CARBON; CARBOXYL GROUP; FENRETINIDE; HYDROXYL GROUP; N (2 CARBOXYPHENYL)RETINAMIDE; N (2 HYDROXYPHENYL)RETINAMIDE; N (3 CARBOXYPHENYL)RETINAMIDE; N (3 HYDROXYPHENYL)RETINAMIDE; N (4 CARBOXYPHENYL)RETINAMIDE; N (4 METHOXYPHENYL)RETINAMIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG STRUCTURE; EMBRYONAL CARCINOMA; GENE DISRUPTION; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, EMBRYONAL; CELL DEATH; CELL DIFFERENTIATION; FENRETINIDE; G1 PHASE; IMMUNOENZYME TECHNIQUES; MICE; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; S PHASE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0141960408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chambon, P. A decade of molecular biology of retinoid receptors. FASEB J., 10: 940-954, 1996.
2. Mangelsdorf, D. J., and Evans, R. M. The RXR heterodimers and orphan receptors. Cell, 83: 841-850, 1995.
3. Lippman, S. M., Benner, S. E., and Hong, W. K. Cancer chemoprevention. J. Clin. Oncol., 12: 851-873, 1994.
4. Kelloff, G. J., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., Greenwald, P., Alberts, D. S., Covey, J. M., Doody, L. A., Knapp, G. G., et al. Clinical development plan: N-(4-hydroxyphenyl) retinamide. J. Cell Biochem., 20 (Suppl.): 176-196, 1994.
5. Formelli, F., Clerici, M., Campa, T., Di Mauro, M. G., Magni, A., Mascotti, G., Moglia, D., De Palo, G., Costa, A., and Veronesi, U. Five-year administration of fenretinide: Pharmacokinetics and effects of plasma retinol concentrations. J. Clin. Oncol., 11: 2036-2042, 1993.
6. Chiesa, F., Tradati, N., Marazza, M., Rossi, N., Boracchi, P., Mariani, L., Formelli, F., Giardini, R., Costa, A., De Palo, G., and et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J. Cell Biochem., 17F (Suppl.): 255-261, 1993.
7. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., DiMauro, M. G., Muraca, M. G., Del Vecchio, M., Pinto, C., D'Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W. F., and Sporn, M. B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 91: 1847-1856, 1999.
8. Hultin, T. A., May, C. M., and Moon, R. C. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metab. Dispos., 14: 714-717, 1986.
9. Formelli, F., Carsana, R., Clerici, M., and Di Mauro, M. G. Fenretinide in chemoprevention of cancer: pharmacological studies. In: G. De Palo, M. Sporn, and U. Veronesi (eds.), Progress and Perspectives in Chemoprevention of Cancer., Vol. 79, pp. 77- 87. New York: Serono Symposia Publications from Raven Press, 1992.
10. Mehta, R. G., Hawthorne, M. E., Moon, R. C., Formelli, F., and Costa, A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer, 27A: 138-141, 1991.
11. Rui, H. Research and development of cancer chemopreventive agents in China. J. Cell Biochem., 27 (Suppl.): 7-11, 1997.
12. D'Ambrosio, S. M., Gibson-D'Ambrosio, R., Milo, G. E., Casto, B., Kelloff, G. J., and Steele, V. E. Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res., 20: 2273-2280, 2000.
13. Clifford, J. L., Sabichi, A. L., Zou, C. C., Yang, X., Steele, V. E., Kelloff, G. J., Lotan, R., and Lippman, S. M. Effects of Novel Phenylretinamides on Cell Growth and Apoptosis in Bladder Cancer. Cancer Epidemol. Biomark. Prev., 10: 391-395, 2001.
14. Sun, S-Y., Yue, P., Kelloff, G. J., Steele, V. E., Lippman, S. M., Hong, W. K., and Lotan, R. Indentification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol. Biomark. Prev., 10: 595-601, 2001.
15. Dmitrovsky, E. N-(4-hydroxyphenyl) retinamide activation of a distinct pathway signaling apoptosis. J. Natl. Cancer Inst., 89: 1179-1181, 1997.
16. Delia, D., Aiello, A., Lombardi, L., Pelicci, P. G., Grignani, F., Grignani, F., Formelli, F., Menard, S., Costa, A., Veronesi, U., and Pierotti, M. A. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res., 53: 6036-6041, 1993.
17. Sheikh, M. S., Shao, Z-M., Li, X-S., Ordonez, J. V., Conley, B. A., Wu, S., Dawson, M. I., Han, Q-X., Chao, W., Quick, T., Niles, R. M., and Fontana, J. A. N-(4-hydroxyphenyl) retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis (Lond.), 16: 2477-2486, 1995.
18. Oridate, N., Lotan, D., Xu, X-C., Hong, W. K., and Lotan, R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res., 2: 855-863, 1996.
19. Kitareewan, S., Spinella, M. J., Allopena, J., Reczek, P. R., and Dmitrovsky, E. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARγ independent pathway. Oncogene, 18: 5747-5755, 1999.
20. Hogan, B. L. M., Barlow, D., and Tilly, R. F9 teratocarcinoma cells as a model for the differentiation of parietal and visceral endoderm in the mouse embryo. Cancer Surv., 2: 115-140, 1983.
21. Clifford, J. L., Chiba, H., Sobieszczuk, D., Metzger, D., and P. Chambon. RXRα-null F9 embryonal carcinoma cells are resistant to the differentiation, antiproliferative and apoptotic effects of retinoids. EMBO J., 15: 4142-4155, 1996.
22. Chiba, H., Clifford, J., Metzger, D., and Chambon, P. Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells. Mol. Cell Biol., 17: 3013-3020, 1997.
23. Clifford, J. L., and Lippman, S. Mechanism of action of the nuclear retinoid receptors. J. Oncol. Index Rev., 1: 3-5, 1997.
24. Rochette-Egly, C., and Chambon, P. F9 embryocarcinoma cells: A cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. Histol. Histopathol., 16: 909-922, 2001.
25. Clifford, J. L., Menter, D. G., Wang, M., Lotan, R., and Lippman, S. M. Retinoid receptor-dependent and -independent effects of N-(4-Hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res., 59: 14-18, 1999.
26. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
27. Chiba, H., Clifford, J. L., Metzger, D., and Chambon, P: Specific and redundant functions of retinoid X receptor-retinoic acid receptor heterodimers in differentiation, proliferation and apoptosis of F9 embryonal carcinoma cells. J. Cell Biol., 139: 735-747, 1997.
28. Wang, S-Y., and Gudas, L. J. Isolation of cDNA clones specific for collagen IV and laminin from mouse teratocarcinoma cells. Proc. Natl. Acad. Sci. USA, 80: 5880-5884, 1983.
29. Lotan, R., Neumann, G., and Lotan, D. Relationships among retinoid structure, inhibition of growth, and cellular retinoic acid-binding protein in cultured S91 melanoma cells. Cancer Res., 40: 1097-1102, 1980.
30. Fanjul, A. N., Delia, D., Pierotti, M. A., Rideout, D., Jian-Qiu, Y., and Pfahl, M. 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem., 271: 22441-22446, 1996.
31. Mehta, R. R., Hawthorne, M. E., Graves, J. M., and Mehta, R. G. Metabolism of N-[4-hyroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur. J. Cancer, 34: 902-907, 1998.
32. Bursch, W., Paffe, S., Putz, B., Barthel, G., and Schulte-Hermann, R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis (Lond.), 11: 847-853, 1990.
33. Boylan, J., Lohnes, D., Taneja, R., Chambon, P., and Gudas, L. J. Loss of RARγ function by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment. Proc. Natl. Acad. Sci. USA, 90: 9601-9605, 1993.
34. Kazmi, S. M. I., Plante, R. K., Visconti, V., and Lau, C. Y. Comparison of N-(4-hydroxyphenyl) retinamide and all-trans retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res., 56: 1056-1062, 1996.
35. Sabichi, A. L., Hendricks, D. T., Bober, M. A., and Birrer, M. J. Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J. Natl. Cancer Inst., 90: 597-605, 1998.
36. Sani, B. P., Shealy, Y. F., and Hill, D. L. N-(4-hydroxyphenyl) retinamide: interactions with retinoid-binding proteins/receptors. Carcinogenesis (Lond.), 16: 2531-2534, 1995.
37. Lippman, S. M., Lee, J. J., and Sabichi, A. Cancer chemoprevention: progress and promise. J. Natl. Cancer Inst., 90: 1514-1528, 1998.
38. Costa, A., Formelli, F., Chiesa, F., Decensi, A., De Palo, G., and Veronesi, U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res., 54 (Suppl.): 20325-20375, 1994.